Scarica l'app Stockscreener
42.01
1.87%
-0.80
Precedente Chiudi:
$42.81
Aprire:
$42.94
Volume 24 ore:
1.20M
Relative Volume:
1.52
Capitalizzazione di mercato:
$2.45B
Reddito:
$776.83M
Utile/perdita netta:
$-29.02M
Rapporto P/E:
-82.05
EPS:
-0.512
Flusso di cassa netto:
$82.25M
1 W Prestazione:
-1.91%
1M Prestazione:
+0.89%
6M Prestazione:
-15.90%
1 anno Prestazione:
-13.17%
Intervallo 1D:
$41.71
$43.29
Intervallo di 1 settimana:
$41.13
$43.41
Portata 52W:
$40.51
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
42.01 | 2.45B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
18.52 | 59.16B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.25 | 48.11B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.44 | 41.51B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.30 | 30.70B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
543.40 | 23.31B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Is Supernus Pharmaceuticals Inc (SUPN) Overvalued After 4.5% Ral - GuruFocus
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - uk.finance.yahoo.com
Supernus Pharmaceuticals, Inc. (SUPN) Stock forecasts - Yahoo Finance Singapore
Supernus Pharmaceuticals (SUPN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo Finance
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Why Did Supernus Pharmaceuticals (SUPN) Move Today? - Yahoo Finance
How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook - Yahoo Finance
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Shares Surge 3.6% -- What GF Score of 87 Tells Investors - GuruFocus
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Supernus at Wells Fargo conference: growth after patent losses By Investing.com - Investing.com Canada
Supernus at Wells Fargo conference: growth after patent losses - Investing.com
Indivior stock gains as Supernus merger and special dividend plan come into focus - ad-hoc-news.de
Supernus at Wells Fargo conference: growth after patent losses By Investing.com - Investing.com South Africa
Supernus at cantor global healthcare conference: merger and growth push By Investing.com - Investing.com Nigeria
Supernus at cantor global healthcare conference: merger and growth push By Investing.com - Investing.com Canada
Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan
SUPN: Strong CNS portfolio growth and a strategic merger position the company for accelerated innovation - TradingView
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD By Investing.com - Investing.com India
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD By Investing.com - Investing.com Canada
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD - investing.com
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD By Investing.com - Investing.com UK
Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de
Supernus Pharmaceuticals Inc. (SUPN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Supernus Pharmaceuticals to Participate in September Investor Conferences - Yahoo Finance
Supernus Pharmaceuticals to Participate in September Investor Conferences - GlobeNewswire
Supernus management will appear at two September conferences in New York and Massachusetts - Stock Titan
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD - Yahoo Finance
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - barchart.com
Supernus Pharmaceuticals Inc. (SUPN) Peer Comparison – Compare with Others - Value Research
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Super - The National Law Review
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? - TradingView
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? - Yahoo Finance
A Look at Supernus Pharmaceuticals Inc (SUPN) After 3.4% Decline -- GF Value $43.78 vs Price $45.85 - GuruFocus
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc. - MarketBeat
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - theglobeandmail.com
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - ad-hoc-news.de
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - Sahm
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - simplywall.st
Britannia, US WorldMeds, Supernus must face US Apokyn antitrust case, plaintiffs say - MLex
Supernus (SUPN) Results Review: The Available Earnings Metric Delivers a Beat in the Latest Reading; After Results: Shares Move 0.35% Lower in the Current UpdateGuidance Revision Trend - vinanet.vn
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Sahm
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rubin Jonathan | SVP, Chief Medical Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
750 |
0 |
14,342 |
| DEC TIMOTHY C | Senior Vice-President & CFO |
Aug 12 '26 |
Option Exercise |
0.00 |
1,250 |
0 |
9,733 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
1,650 |
0 |
20,341 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Aug 12 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
19,795 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| PADMANABH P BHATT | Officer |
Mar 17 '26 |
Proposed Sale |
50.21 |
57,250 |
2,874,522 |
0 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Option Exercise |
38.51 |
50,000 |
1,925,537 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
3.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):